|
|
Fulcrum Therapeutics Inc (NASDAQ: FULC) |
|
Price: $3.8900
$0.04 
1.039%
|
| Day's High:
| $3.9149999618530273
| Week Perf:
| 0.78 %
|
| Day's Low: |
$ 3.80 |
30 Day Perf: |
8.66 % |
| Volume (M): |
1,797,541 |
52 Wk High: |
$ 15.74 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$7.62 |
| Open: |
$3.83 |
52 Wk Low: |
$2.83 |
|
|
| Market Capitalization (Millions $) |
296 |
| Shares
Outstanding (Millions) |
76 |
| Employees |
55 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-76 |
| Cash Flow (TTM) (Millions $) |
8 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing small molecule therapies to treat genetically defined diseases. The company specializes in identifying and targeting key regulatory control points within cells to restore essential gene control mechanisms. Fulcrum Therapeutics aims to address the root causes of diseases such as neurodevelopmental disorders, rare diseases, and genetic muscular disorders. The company utilizes its proprietary product engine to identify potential drug candidates and advance them through preclinical and clinical development.
Company Address: 26 Landsdowne Street Zagreb 2139 City of Zagreb
Company Phone Number: 651-8851 Stock Exchange / Ticker: NASDAQ FULC
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Shares
Published Fri, May 9 2025 8:30 PM UTC
Fulcrum Therapeutics Expands Workforce Through Inducement Stock Option Grants: A Strategic Move Compliant with Nasdaq Listing RulesFulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is making significant strides in its corporate strategy by enhancing its workforce. In a series of announcements span...
|
| Shares
Published Fri, Apr 11 2025 8:30 PM UTC
CAMBRIDGE, Mass. April 11, 2025 Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to enhance the lives of patients with genetically defined rare diseases, recently announced an important step in expanding its workforce. The company granted nonstatutory stock options to two new employees in accordance...
|
| Announcement
Published Wed, Sep 25 2024 8:00 PM UTC
Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a prominent player in the biopharmaceutical industry, is currently under investigation by Bronstein, Gewirtz & Grossman, LLC. This development has sent ripples of concern through the investor community, with many seeking to understand the underlying causes and potential implications of this scrutiny.Bronstein, Gewirtz & Grossman, LL...
|
| Announcement
Published Thu, Sep 19 2024 8:00 PM UTC
: The pharmaceutical sector is often characterized by rapid fluctuations in stock prices, driven by a multitude of factors including clinical trial outcomes, regulatory developments, and market dynamics. Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a company focused on advancing precision medicine for patients with genetically-driven diseases, has recently become the subject o...
|
| Announcement
Published Fri, Sep 13 2024 8:00 PM UTC
NEW YORK, Sept. 13, 2024 Investors holding securities of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) should be aware of an important development. Bronstein, Gewirtz & Grossman, LLC, a renowned law firm specializing in securities litigation, has announced an investigation into potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. Details of the Investigatio...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-1.16 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
0.11 $ |
| Cash |
4.37 $
|
| Book Value |
4.37 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
- |
| Net
Income per Employee (TTM) |
-1,383,927 |
| Receivable Turnover Ratio (TTM) |
- |
| Inventory Turnover Ratio (TTM) |
- |
| Asset Turnover Ratio (TTM) |
- |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.16 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
0.11 $ |
| Cash |
4.37 $
|
| Book Value |
4.37 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
1.75%